The DOI matches its Crossref record.
Ruthenium Anticancer Compounds: Challenges and Expectations
Open accessAbstract
Two ruthenium compounds, namely [ImH]trans-[RuCl4(Im)(dmso-S)] (NAMI-A, Im = imidazole) and [IndH] trans-[RuCl4(Ind)2] (KP1019, Ind = indazole) have already completed phase I clinical trials as anticancer agents. They both have properties different from platinum anticancer drugs: for example, NAMI-A is selectively active against metastases of solid tumors. They show that in the field of anticancer metal drugs a new approach, based on targeted therapies, is possible. After a concise history of ruthenium anticancer compounds, this contribution will focus on ruthenium-dmso complexes and, in particular, on NAMI-A. Particular emphasis is given on the challenges that are inherent to this field: how to develop new anticancer ruthenium compounds and how to select new active compounds that manifest their anticancer activity through non-conventional mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fluorescent chemical probes for accurate tumor diagnosis and targeting therapy
Gao, M., Yu, F., Lv, C., Choo, J., & Chen, L. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00908e · Cited by 827
Next-Generation Metal Anticancer Complexes: Multitargeting via Redox Modulation
Romero-Canelón, I., & Sadler, P. J. (2013) · Inorganic Chemistry · doi:10.1021/ic400835n · Cited by 396
Metadata
- Authors
- Bratsos, I., Jedner, S., Gianferrara, T., & Alessio, E.
- Venue
- CHIMIA
- Publisher
- Swiss Chemical Society
- Published
- 2007-11-28
- Volume
- 61
- Issue
- 11
- Pages
- 692
- ISSN
- 0009-4293 (ISSN-L)
- 2673-2424
- OpenAlex
- W2147450568
- Cited by
- 225
- References
- 0
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ruthenium Anticancer Compounds: Challenges and Expectations. https://app.cochat.ai/papers/10.2533/chimia.2007.692
- The paper
- Bratsos, I., Jedner, S., Gianferrara, T., & Alessio, E. (2007). Ruthenium Anticancer Compounds: Challenges and Expectations. CHIMIA. https://doi.org/10.2533/chimia.2007.692
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
